Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 3/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338105 | 0.84 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GHSD11B1SYKALDH1A1 | |
| SCHEMBL25339261 | 0.84 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GSYKALDH1A1KDM4E | |
| SCHEMBL21997075 | 0.84 | APOBEC3A (0.43) | APOBEC3AAPOBEC3GHRH3ALDH1A1KDM4E | |
| SCHEMBL25339582 | 0.84 | APOBEC3A (0.43) | PTGER4APOBEC3AAPOBEC3GSYKALDH1A1 | |
| SCHEMBL25339426 | 0.83 | APOBEC3A (0.39) | PTGER4APOBEC3AAPOBEC3GSYKKIF18A | |
| SCHEMBL21996782 | 0.83 | APOBEC3A (0.46) | APOBEC3AAPOBEC3GHSD11B1SYKALDH1A1 | |
| SCHEMBL21996998 | 0.81 | KMO (0.50) | APOBEC3AAPOBEC3GALDH1A1KDM4E | |
| SCHEMBL25341150 | 0.80 | KDM4E (0.43) | APOBEC3AAPOBEC3GALDH1A1KDM4E | |
| SCHEMBL21997705 | 0.80 | SMPD3 (0.47) | PTGER4APOBEC3AAPOBEC3GHSD11B1ADORA2A | |
| SCHEMBL25337091 | 0.79 | APOBEC3A (0.38) | APOBEC3AAPOBEC3GSYKKIF18AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PTGER4 3404/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PTGER4 3404/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PTGER4 3404/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PTGER4 3404/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.